Try our Advanced Search for more refined results

Expert Analysis

What Really Doomed Kidney Test Patents In Fed. Circ. Ruling

By Javier Mixco, Cory Smith and George Chen (December 16, 2022, 5:08 PM EST) -- In the CareDx Inc. v. Natera Inc. decision, the U.S. Court of Appeals for the Federal Circuit added to the long line of patent eligibility rulings — holding the patents that Stanford University and its exclusive licensee CareDx Inc. asserted against Natera Inc. and Eurofins Viracor Inc. were patent-ineligible because they attempted to claim the use of natural phenomena with well-known techniques to diagnose organ transplant rejection.[1] ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!